SIETES :: 93097 citas

Resultados de la búsqueda por EPOETINAS REFINAR BÚSQUEDA

1.

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]

2.

Aronson JK, Ferner RE. How similar are biosimilars?. BMJ 2016;353:i2721. [Ref.ID 100310]

3.

McCarthy M. Erythropoietin stimulating agents do not significantly improve quality of life in chronic kidney disease, study finds. BMJ 2016;352:i931. [Ref.ID 100057]

4.

Larráyoz B. Medicamentos biosimilares. Concepto, regulación y controversias en su utilización. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-11. [Ref.ID 99826]

5.

Robles NR, Macías JF, Herrera J. Uso de agentes estimuladores de la reitropoyesis en pacientes con insuficiencia cardíaca congestiva. Med Clin (Barc) 2014;142:215-8. [Ref.ID 97268]

6.

Coyne DW. Anemia in chronic kidney disease: treating the numbers, not the patients. JAMA Intern Med 2014;174:708-9. [Ref.ID 97192]

7.

Kansagara D, Dyer E, Englander H, Fu R, Freeman M. Treatment of anemia in patients with heart disease: a systematic review. Ann Intern Med 2013;159:746-57. [Ref.ID 96652]

8.

Avorn J. Healing the overwhelmed physician. N Y Times (Print) 2013:11 de junio. [Ref.ID 95635]

9.

Heuberger JAAC, Tervaert JMC, Schepers FML, Vliegenthart ADB, Rotmans JI, Daniels JMA, Burggraaf J, Cohen AF. Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit. Br J Clin Pharmacol 2013;75:1406-21. [Ref.ID 95567]

10.

Anónimo. What are biosimilars and are they important?. Drug Ther Bull 2013;51:57-60. [Ref.ID 95385]

11.

Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 2013;173:611-2. [Ref.ID 95286]

12.

Drüeke TB. Anemia treatment in patients with chronic kidney disease. N Engl J Med 2013;368:387-9. [Ref.ID 94809]

13.

Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM, Fishbane S, PEARL Study Groups. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320-32. [Ref.ID 94806]

14.

Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duilege A-M, Besarab A, for the EMERALD Study Groups. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19. [Ref.ID 94805]

15.

Arneson TJ, Li S, Gilbertson DT, Bridges KR, Acquavella JF, Collins AJ. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients. Pharmacoepidemiol Drug Saf 2012;21:857-64. [Ref.ID 93529]

16.

Hawkes N. Performance enhancing drugs or techniques may exist that can't yet be detected, experts admit. BMJ 2012;345:3. [Ref.ID 93483]

17.

Yuki N, Hartung H-P. Medical progress: Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304. [Ref.ID 93212]

18.

Anónimo. Peginesatide (Omontys) for anemia in chronic kidney disease. Med Lett Drugs Ther 2012;54:45-6. [Ref.ID 93204]

19.

Epstein K. Full results on risk of epoetin emerge 14 years after study. BMJ 2012;344:2. [Ref.ID 92999]

20.

Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB, ESA Clinic Study Group. Impact of pharmacist-managed erythropoiesis - Stimulating agents clinics for patients with non-dialysis-dependent CKD. Am J Kidney Dis 2012;60:371-9. [Ref.ID 92943]